Company / Depreciation & Amortization
TG Therapeutics, Inc. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$59.0K
FY2025
5-year range
$59.0K / $303.0K
FY2021-FY2025
Trend
-13.2%
vs FY2024
Sector context
#162 of 168
Health Care
What the data says
Among 168 Health Care companies, TG Therapeutics, Inc. is in the top 4% for depreciation & amortization. Depreciation & Amortization has declined for 3 consecutive years, from $303,000 in FY2022 to $59,000 in FY2025.
Based on SEC 10-K filings.
$59,000 in FY2025 with a 3-year CAGR of -42.0%.
Improved from $211,000 to $59,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -42.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 168This company $59.0K Sector average $212.9M
▼
-100.0% below sector average
Key checks
Key Insights
- TG Therapeutics, Inc.'s depreciation & amortization has declined for 3 consecutive years.
- 3-year CAGR of -42.0%, indicating a declining trend.
- In FY2025, depreciation & amortization decreased 13.2% year-over-year.
- Ranks #162 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $59.0K | -13.2% |
| FY2024 | $68.0K | -67.8% |
| FY2023 | $211.0K | -30.4% |
| FY2022 | $303.0K | +7.4% |
| FY2021 | $282.0K | - |
| FY2020 | - | - |
| FY2019 | $82.0K | - |
| FY2018 | - | - |
| FY2017 | $82.0K | +30.2% |
| FY2016 | $63.0K | +307.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026